Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of D326, D337 and CKD-828 in Healthy Subjects
NCT03726866Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + levamlodipine in hypertension (HTN) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum plasma concentration at Day 9 and Area under the plasma concentration-time curve over the dosing interval at Day 9. Status: unknown.
02
Drugs
telmisartan + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03726866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726866.